daiichisankyo.usPassion for innovation. Compassion for patients. - Daiichi Sankyo US

Passion for innovation. Compassion for Patients. Healthcare Professionals | Careers | Contact Us | Worldwide | SearchSearch Search Daiichi Sankyo, Inc.Who We Are Values and Mission Company Culture Global Business Strategy and Midterm Plan History Corporate Philanthropy Partnerships Business Development Alliances At-A-Glance Corporate Information Corporate Management Company Governance and Global Structure Corporate Brochure Patient Advocacy Responsibility Responsibility Compliance Standards Of Business Conduct Standards of Business Conduct & Ethics for Third Parties Daiichi Sankyo Group Global Anti-Bribery and Anti-Corruption Policy California Compliance Declaration California Supply Chains Act Daiichi Sankyo Group Employee Code of Conduct Transparency and Disclosure Post-marketing Commitments CME and Charitable Contributions Disclosure Working with Healthcare Professionals Vermont Pharmaceutical Marketer Price Disclosure Clinical Trial Information Disclosure Corporate Giving and Support Daiichi Sankyo Requirements Charitable Contributions Sponsorships Corporate Support FAQs Patient Advocacy Support Independent Medical Education (IME) Daiichi Sankyo Patient Support Programs Supplier Diversity Supplier Registration Supplier Diversity FAQs Transparency in Coverage Rights & Protections Against Surprise Medical Bills Research & Development Research & Development Our Pipeline Worldwide R&D Operations Clinical Trial Information Disclosure Expanded Access to Investigational Products External Sponsored Research (ESR) Investigator Initiated Studies (IIS) and Collaborative Research (CR) Medicines Media Our Stories Search Search ButtonWho We Are Who We Are Values and Mission Company Culture Global Business Strategy and Midterm Plan History Corporate Philanthropy Partnerships Partnerships Business Development Alliances At-A-Glance Corporate Information Corporate Information Corporate Management Company Governance and Global Structure Corporate Brochure Patient Advocacy Responsibility Compliance Compliance Standards Of Business Conduct Standards of Business Conduct & Ethics for Third Parties Daiichi Sankyo Group Global Anti-Bribery and Anti-Corruption Policy California Compliance Declaration California Supply Chains Act Daiichi Sankyo Group Employee Code of Conduct Transparency and Disclosure Transparency and Disclosure Post-marketing Commitments CME and Charitable Contributions Disclosure Working with Healthcare Professionals Vermont Pharmaceutical Marketer Price Disclosure Clinical Trial Information Disclosure Corporate Giving and Support Corporate Giving and Support Daiichi Sankyo Requirements Charitable Contributions Sponsorships Corporate Support FAQs Patient Advocacy Support Independent Medical Education (IME) Daiichi Sankyo Patient Support Programs Supplier Diversity Supplier Diversity Supplier Registration Supplier Diversity FAQs Transparency in Coverage Rights & Protections Against Surprise Medical Bills Research & Development Our Pipeline Worldwide R&D Operations Clinical Trial Information Disclosure Expanded Access to Investigational Products External Sponsored Research (ESR) Investigator Initiated Studies (IIS) and Collaborative Research (CR) Medicines Media Our Stories Healthcare Professionals Careers Contact Us HOME_PAGE_HEADER_CONTENT Passion for Innovation. Compassion for Patients. Learn More-HP Updated Learn Moreand the role of family and mentorship in her pursuit of a fulfilling career. read more Former Heart Surgeon Finds Rewarding Career Outside the OR Michael Grosso talks open heart surgery, Specialty Medicine, and Astronomy. read more Featured News Press Releases Email Alert Mon Apr 29 00:00:00 GMT-05:00 2024 NEW ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial Download Fri Apr 05 00:00:00 GMT-05:00 2024 ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors Download Wed Apr 03 00:00:00 GMT-05:00 2024 REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer Download Tue Apr 02 00:00:00 GMT-05:00 2024 Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer Download View AllWho We Are Partnerships Corporate Information Patient Advocacy Responsibility Compliance Transparency and Disclosure Corporate Giving and Support Daiichi Sankyo Patient Support Programs Supplier Diversity Transparency in Coverage Rights & Protections Against Surprise Medical Bills Research & Development Our Pipeline Worldwide R&D Operations Clinical Trial Information Disclosure Expanded Access to Investigational Products External Sponsored Research (ESR) Investigator Initiated Studies (IIS) and Collaborative Research (CR) Medicines Media Our Stories LinkedIn Twitter Facebook Youtube Disclaimer Data Protection Notice Social Media PolicyTerms & Conditions Privacy Notice Contact Us Site Map © 2024 Daiichi Sankyo, Inc. All Rights Reserved.Worldwide Daiichi Sankyo Co., Ltd - Global Asia Japan China Hong Kong Korea Taiwan Thailand Vietnam Americas Brazil USA Daiichi Sankyo, Inc. American Regent, Inc. Plexxikon Europe Daiichi Sankyo Europe Austria Belgium France Germany Ireland Italy Portugal Spain Switzerland The Netherlands Turkey United Kingdom Continue...